It was later discovered that one of the donors was HIV positive, leading to her infection..HIV, AIDS, Cancer patient, RCC, Kerala High Court ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

A groundbreaking annual injection designed to protect against HIV has successfully passed its first safety trial, bringing new hope for long-term prevention.The drug, Lenacapavir, prevents the virus ...

Prof. Francisca Mutapi, a global health expert suggests 4 ways to end the dependence HEALTH | FRANCISCA MUTAPI | There’s been a global trend in the reduction of aid to Africa since 2018. Donors are ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

Providing feedback following point-of-care urine testing for tenofovir concentrations was associated with increased PrEP ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

PEPFAR, a global program to combat AIDS, faces an existential threat due to partisan politics, but Congress has an opportunity to reform the program and ensure its continued success.

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. Colorized transmission electron micrograph of immature mpox virus particles (blue with red viral envelope) ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...